Palisade Bio, Inc., a clinical-stage biopharmaceutical company, focuses on developing and advancing novel therapeutics for patients living with autoimmune, inflammatory, and fibrotic diseases. The company's lead therapeutic candidate is PALI-2108, a prodrug PDE4 inhibitor that is in phase 1a/b clinical trial for the treatment of ulcerative colitis, as well as under phase 1a clinical trial for the treatment of fibrostenotic crohn's disease. It has a research collaboration and license agreement with Giiant Pharma, Inc. for the development, manufacture, and commercialization of its compounds; a license agreement with the Regents of the University of California for sole purpose of maintaining the Newsoara Co-Development; and a co-development and distribution agreement with Newsoara Biopharma Co., Ltd. The company is headquartered in Carlsbad, California. Show more
Location: 7750 El Camino Real, Carlsbad, CA, 92009, United States | Website: https://www.palisadebio.com | Industry: Biotechnology | Sector: Healthcare
Market Cap
3.762M
52 Wk Range
$0.60 - $4.89
Previous Close
$0.78
Open
$0.77
Volume
120,021
Day Range
$0.75 - $0.79
Enterprise Value
-3.92M
Cash
7.242M
Avg Qtr Burn
-2.837M
Insider Ownership
0.46%
Institutional Own.
5.43%
Qtr Updated
03/31/25
Drug Pipeline
Powered by

Only showing assets and stage. See catalyst data with a free or premium account. Unlock more data with a free account.
Drug & Indication | Stage & Event | Catalyst Date |
---|---|---|
PALI-2108 Details Ulcerative colitis | Phase 2 Initiation |